JP2021527418A5 - - Google Patents

Info

Publication number
JP2021527418A5
JP2021527418A5 JP2020570457A JP2020570457A JP2021527418A5 JP 2021527418 A5 JP2021527418 A5 JP 2021527418A5 JP 2020570457 A JP2020570457 A JP 2020570457A JP 2020570457 A JP2020570457 A JP 2020570457A JP 2021527418 A5 JP2021527418 A5 JP 2021527418A5
Authority
JP
Japan
Prior art keywords
seq
domain
polynucleotide
sequence
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527418A (ja
JP7534961B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037769 external-priority patent/WO2019246125A1/en
Publication of JP2021527418A publication Critical patent/JP2021527418A/ja
Publication of JP2021527418A5 publication Critical patent/JP2021527418A5/ja
Priority to JP2024127744A priority Critical patent/JP2024156872A/ja
Application granted granted Critical
Publication of JP7534961B2 publication Critical patent/JP7534961B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570457A 2018-06-18 2019-06-18 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法 Active JP7534961B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024127744A JP2024156872A (ja) 2018-06-18 2024-08-02 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862686522P 2018-06-18 2018-06-18
US62/686,522 2018-06-18
PCT/US2019/037769 WO2019246125A1 (en) 2018-06-18 2019-06-18 Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024127744A Division JP2024156872A (ja) 2018-06-18 2024-08-02 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法

Publications (3)

Publication Number Publication Date
JP2021527418A JP2021527418A (ja) 2021-10-14
JP2021527418A5 true JP2021527418A5 (https=) 2022-06-28
JP7534961B2 JP7534961B2 (ja) 2024-08-15

Family

ID=67263074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570457A Active JP7534961B2 (ja) 2018-06-18 2019-06-18 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法
JP2024127744A Pending JP2024156872A (ja) 2018-06-18 2024-08-02 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024127744A Pending JP2024156872A (ja) 2018-06-18 2024-08-02 ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法

Country Status (6)

Country Link
US (1) US20240254181A1 (https=)
EP (1) EP3807309A1 (https=)
JP (2) JP7534961B2 (https=)
AU (2) AU2019288291B2 (https=)
CA (1) CA3104471A1 (https=)
WO (1) WO2019246125A1 (https=)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514481B1 (en) * 1990-01-30 2000-05-03 La Jolla Cancer Research Foundation Merosin, nucleic acids encoding, fragments and uses thereof
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001500497A (ja) 1996-09-06 2001-01-16 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
US20110166081A1 (en) * 2009-12-03 2011-07-07 University Of Iowa Research Foundation Alpha-dystroglycan as a Protein Therapeutic
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
IL258005B2 (en) 2015-09-17 2025-01-01 Res Inst Nationwide Childrens Hospital Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2
ES2977730T3 (es) 2016-04-15 2024-08-29 Res Inst Nationwide Childrens Hospital Administración de microARN-29 y micro-distrofina por virus adenoasociado para tratar la distrofia muscular
WO2018151841A1 (en) * 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2

Similar Documents

Publication Publication Date Title
KR102298579B1 (ko) 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
EP2623605B1 (en) RAAV vector compositions having tyrosine-modified capsid proteins and methods for use
CA2407309A1 (en) Dna sequences encoding dystrophin minigenes and methods of use thereof
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2020510428A5 (https=)
JP2021534809A (ja) Aavカプシドの向性の再指向化
JP2020510429A5 (https=)
JP2019515663A5 (https=)
CN110950934B (zh) 一种腺相关病毒衣壳蛋白、载体及其构建方法与应用
RU2019126509A (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
CN116096904A (zh) 改进的aav-abcd1构建体和用于治疗或预防肾上腺脑白质营养不良(ald)和/或肾上腺脊髓神经病(amn)的用途
RU2760301C1 (ru) Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2
JP2023534293A5 (https=)
JP2021534794A5 (https=)
AU2021331947A9 (en) Aav5-based vaccine against sars-cov-2
WO2013159036A1 (en) Adeno associated virus plasmids and vectors
JP2021527418A5 (https=)
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのaqp1遺伝子療法
CN117003833A (zh) 肝脏特异性的腺相关病毒血清型及应用
RU2856244C2 (ru) Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2
CN112695032B (zh) 一种启动子pLRRK2及其应用
CN115160410A (zh) 新型肌肉高效亲和腺相关病毒血清型及相关应用
WO2024249438A1 (en) Copiparvovirus genetic vector platform
EP4676939A1 (en) Novel compositions of adeno-associated viruses engineered for enhanced tissue transduction and specificity
WO2025170636A2 (en) Methods of risk assessment for muscular dystrophy gene therapy